Cosentyx carries a list price of $7,936 per month, making it one of the more expensive medications on the market. Several factors drive that price tag: it’s a biologic drug that’s complex to manufacture, it’s still protected by patents with no cheaper alternatives available, and the U.S. pricing system allows drugmakers to set prices far higher than what patients in other countries pay.
What Cosentyx Actually Costs
As of July 2025, Novartis lists Cosentyx at $7,936.48 per month for either the 150 mg or 300 mg self-injection package. An intravenous infusion costs $4,401.32 per dose. For patients on a standard maintenance schedule, that works out to roughly $95,000 per year at list price for the injectable form.
What you actually pay depends heavily on your insurance. Medicare Part D plans cover Cosentyx, but your out-of-pocket share varies by plan. Many commercial insurers place biologics like Cosentyx on specialty tiers, which typically require coinsurance (a percentage of the drug’s cost) rather than a flat copay. Even with insurance, monthly costs can run into hundreds or thousands of dollars before any manufacturer assistance programs kick in. Novartis has announced a 55% discount for cash-paying patients, bringing the price closer to $3,570 per month for those without insurance coverage.
Biologics Are Expensive to Make
Cosentyx isn’t a pill synthesized from simple chemical reactions. It’s a biologic, meaning it’s produced using living cells that are engineered to create a specific protein. That protein targets and blocks a single immune signaling molecule involved in inflammatory conditions like psoriasis, psoriatic arthritis, and ankylosing spondylitis.
Manufacturing biologics requires specialized facilities with tightly controlled conditions. The living cells must be grown in large bioreactors, and the final product has to be purified, tested for consistency, and kept refrigerated throughout the supply chain. Any small variation in the process can change the drug’s effectiveness or safety profile. This level of complexity costs significantly more than producing a conventional pill, and drugmakers pass those costs along in the price.
Patent Protection Blocks Competition
One of the biggest reasons Cosentyx remains expensive is that no biosimilar (the biologic equivalent of a generic drug) is available in the United States. Patent protection for the active ingredient is expected to last until 2028 in the U.S., 2030 in Europe, and 2029 in Japan. Until those patents expire and biosimilar manufacturers can enter the market, Novartis faces no direct price competition for Cosentyx.
When biosimilars do eventually arrive, history suggests prices could drop meaningfully. Biosimilar competition for other biologics has led to price reductions of 30% to 50% or more. But developing a biosimilar still takes years of testing to demonstrate it works the same way as the original, so lower-cost versions won’t appear overnight once patents expire.
The U.S. Pays Far More Than Other Countries
The price gap between the U.S. and other countries is striking. In the United Kingdom, the NHS list price for Cosentyx works out to roughly $9,750 (converted from £7,312.68) per year after the first year of treatment. That’s about one-tenth of the U.S. annual list price. And the actual price the NHS pays is even lower, because the UK’s National Institute for Health and Care Excellence negotiated a confidential discount with Novartis on top of the list price.
This disparity exists because most other wealthy countries have government agencies that negotiate drug prices directly with manufacturers or set maximum price thresholds. The U.S. has historically allowed drugmakers to set their own prices, with limited government negotiation power. Medicare only recently gained authority to negotiate prices on a small number of drugs, and Cosentyx is not currently among them.
How Rebates Inflate the Sticker Price
The list price you see for Cosentyx isn’t what most insurers actually pay. Pharmacy benefit managers, the middlemen who negotiate drug coverage for insurance plans, extract significant rebates from manufacturers. These rebates are the price of getting a drug placed on a favorable coverage tier so that doctors and patients can access it without excessive hurdles.
The problem is that these rebates are calculated as a percentage of the list price. A higher list price means a bigger rebate in dollar terms, which gives both manufacturers and pharmacy benefit managers a financial incentive to keep list prices high. Drug manufacturers have argued publicly that growing rebate demands force them to raise list prices. Meanwhile, evidence from the Commonwealth Fund shows that pharmacy benefit managers sometimes negotiate rebates that are contingent on excluding lower-cost competitor drugs from coverage or placing them on more expensive tiers, further reducing competitive pressure on pricing.
The result is a system where the official price climbs while the actual amount changing hands between insurer and manufacturer may be considerably lower. Patients with coinsurance, however, often have their cost-sharing calculated based on the inflated list price rather than the discounted net price, meaning they absorb a disproportionate share of the cost.
What This Means for Your Out-of-Pocket Costs
If you’re prescribed Cosentyx, your actual costs depend on several variables: your insurance type, your plan’s formulary tier for the drug, whether you’ve met your deductible, and whether you qualify for any assistance programs. Novartis offers a copay card for commercially insured patients that can reduce costs significantly, and the 55% cash-pay discount provides an option for uninsured patients.
For Medicare Part D enrollees, the Inflation Reduction Act’s $2,000 annual out-of-pocket cap on prescription drugs (effective 2025) provides a ceiling on total spending, though reaching that cap on a single medication like Cosentyx can happen within the first month or two of treatment. If you’re facing high costs, specialty pharmacies and patient advocacy organizations can sometimes help identify additional savings programs or alternative coverage pathways.